Company advances candidate targeting senescent cells into US study with potential applications beyond dermatology.
Rubedo Life Sciences has announced that the US Food and Drug Administration has cleared its Investigational New Drug application for RLS-1496, a selective modulator of glutathione peroxidase 4 (GPX4). The company will now move into a Phase 1b/2a trial in patients with actinic keratosis, beginning in the fourth quarter of 2025. This follows the start of a European trial earlier this year, in which RLS-1496 is being tested in plaque psoriasis, atopic dermatitis and photoaged skin, with results expected around the same time.
The new clearance represents the second study accepted for RLS-1496, a compound designed to target pathological senescent cells and restore tissue homeostasis by sensitizing them to ferroptosis – a form of programmed cell death. The approach was discovered through Rubedo’s proprietary AI-driven ALEMBIC platform, which identifies targets and designs small molecules aimed at dysfunctional, aged cells.
Longevity.Technology: GPX4 modulation is a bold play in the senotherapeutics arena – ferroptosis may be the zombie cells’ Achilles’ heel, but it is also a pathway that underpins normal cellular metabolism, and tipping the balance too far could risk collateral damage. That said, novelty is the lifeblood of longevity biotech; a field that relies on repurposing the same handful of pathways will not deliver the breakthroughs we need. By pursuing an unconventional mechanism, Rubedo is not only pushing the therapeutic envelope but also daring regulators and investors to broaden their horizons on what counts as a legitimate antiaging strategy.
If RLS-1496 can demonstrate clear, safe senescent cell clearance in humans – and not just in conveniently accessible skin conditions – the implications will ripple far beyond dermatology. Oral formulations raise tantalizing possibilities for systemic applications in fibrosis, sarcopenia and neurodegeneration; however, translating topical success into whole-body rejuvenation is a leap, not a hop. Still, every regulatory green light and every patient dosed brings the field closer to an era where ‘disease-modifying’ no longer refers only to oncology or autoimmune disorders but becomes part of the mainstream lexicon of aging medicine – and that is a shift worth watching.
A first-in-class approach
RLS-1496 is being developed both as a topical and oral therapy. In preclinical studies Rubedo has shown that GPX4 imbalance in certain aged cells makes them vulnerable to ferroptosis, a vulnerability the company is seeking to exploit. By clearing senescent cells, the compound aims to reduce the inflammatory environment they create and to support the recovery of normal tissue function.
CEO Frederick Beddingfield described the new milestone as a chance to widen impact. “We are thrilled to reach another important milestone with our lead candidate RLS-1496,” he said. “This second IND clearance supports our focus on the potential of RLS-1496 as the first-ever GPX4 modulator to treat an array of age-related diseases and conditions, which will allow us to have the greatest impact for patients.”
Expanding beyond skin
Although actinic keratosis is the immediate focus for the new trial, Rubedo has always presented RLS-1496 as a platform compound with broader relevance. Actinic keratosis itself is highly prevalent – affecting around 20% of people in the United States and approximately 14% globally [1,2] – and left untreated, lesions may progress to skin cancer. Psoriasis, the target of Rubedo’s European study, affects about 3% of adults in the US and 4.4% worldwide [3,4], while atopic dermatitis affects 7.3% of US adults and roughly 2% of adults globally [5,6]; together, these figures highlight the scale of age-associated dermatological disease that might be addressed through selective senotherapeutics.
While Rubedo’s long-term focus is clearly on systemic applications, skin health remains a significant market in its own right; demand for treatments that address inflammatory conditions and visible signs of aging is substantial, offering both a commercial opportunity and a proving ground for senotherapeutic approaches.
Chief scientific officer Marco Quarta highlighted the breadth of potential applications. “This IND clearance comes just four months after the initiation of a Phase 1 study with RLS-1496 in patients with psoriasis in Europe,” he said. “We are excited to begin this new trial and showcase the breadth of therapeutic impact that can be made by targeting inflammatory and aging mechanisms like GPX4.”
Building clinical expertise
Rubedo is also continuing to build out its clinical advisory board, bringing in experienced clinicians to provide strategic and scientific guidance. The latest addition is dermatologist and immunologist Emma Guttman-Yassky of Mount Sinai, New York, who joins an already well-established panel led by Rubedo’s chief medical officer Mary Spellman. The presence of high-profile advisors is intended to support clinical translation and to strengthen the company’s positioning as it moves deeper into trials across both dermatology and systemic indications.
A wider horizon
The pace at which Rubedo has moved from platform discovery through to dual clinical trials – with regulatory clearances in both Europe and the US – demonstrates both the company’s ambition and the growing willingness of regulators to consider therapies explicitly aimed at senescent cells. Yet the central questions remain unresolved: can GPX4 modulation selectively dismantle dysfunctional cells while sparing the healthy, and will systemic delivery prove feasible and safe?
Rubedo has made clear that its ambition is to move beyond cosmetic or dermatological benefits and into the realm of chronic disease modification. Whether the promise of ferroptosis as a lever against cellular senescence can be harnessed without unintended consequences will determine whether RLS-1496 is remembered as a curious dermatology experiment or as the first of a new class of antiaging medicines.
An age of definition
The regulatory milestones achieved this year matter – not only to Rubedo but to the longevity field as a whole. As biotech companies pursue age-related indications by proxy, success will gradually shape how ‘aging’ is defined in clinical and policy terms. The prospect of senotherapeutics crossing from topical skin formulations into oral systemic treatments points to a future in which the boundary between treating disease and modifying the biology of aging becomes progressively less distinct.
Photograph: alicerubik2/Envato. Photograph of Marco Quarta courtesy of Rubedo.
[1] https://www.jaad.org/article/S0190-9622(12)01064-X/abstract
[2] https://doi.org/10.1093/bjd/ljad371
[3] https://jamanetwork.com/journals/jamadermatology/fullarticle/2781378
[4] https://doi.org/10.2340/actadv.v105.42945
[5] https://aafa.org/asthma-allergy-research/our-research/atopic-dermatitis-in-america/
[6] https://doi.org/10.1093/bjd/ljad339
